the development of these in vitro and other systems for detecting a compound’s nephrotoxicity potential.
Dieterle, F., E. Marrer, E. Suzuki, O. Grenet, A. Cordier, and J. Vonderscher. 2008. Monitor-Monitoring kidney safety in drug development: Emerging technologies and their implications. Current Opinion in Drug Discovery & Development 11(1):60–71.
Ferguson, M. A., V. S. Vaidya, and J. V. Bonventre. 2008. Biomarkers of nephrotoxic acute kidney injury. Toxicology 245(3):182–193.
Knight, A. 2008. Systematic reviews of animal experiments demonstrate poor contributions toward human healthcare. Reviews on Recent Clinical Trials 3(2):89–96.
Kola, I., and J. Landis. 2004. Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug Discovery 3(8):711–715.
Olson, H., G. Betton, D. Robinson, K. Thomas, A. Monro, G. Kolaja, P. Lilly, J. Sanders, G. Sipes, W. Bracken, M. Dorato, K. Van Deun, P. Smith, B. Berger, and A. Heller. 2000. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology: RTP 32(1):56–67.
Pannu, N., and M. K. Nadim. 2008. An overview of drug-induced acute kidney injury. Critical Care Medicine 36(Suppl. 4):S216–S223.
Parikh, C. R., and P. Devarajan. 2008. New biomarkers of acute kidney injury. Critical Care Medicine 36(Suppl. 4):S159–S165.
Sistare, F. D., and J. J. DeGeorge. 2007. Preclinical predictors of clinical safety: Opportunities for improvement. Clinical Pharmacology and Therapeutics 82(2):210–214.
Sistare, F. D., and J. J. DeGeorge. 2008. Applications of toxicogenomics to nonclinical drug development: Regulatory science considerations. Methods in Molecular Biology 460:239–261.
Wagner, J. A., S. A. Williams, and C. J. Webster. 2007. Biomarkers and surrogate endpoints for fit-for-purpose development and regulatory evaluation of new drugs. Clinical Pharmacology and Therapeutics 81:104–107.